A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2504320122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Jiawei Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, …. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, RNA, Circular, RNA-Binding Proteins, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Foundation of Sichuan Province, China, the Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Bromodomain-and-extraterminal-domain (BET) proteins are promising therapeutic targets for refractory solid tumors, including triple-negative breast cancer (TNBC). However, acquired resistance to BET inhibitors (BETi) remains a significant clinical challenge. Elucidation of the underlying mechanisms of BETi resistance is therefore of critical importance. In this study, we identified the RNA-binding protein IGF2BP2 as a key driver of acquired BETi resistance in TNBC, primarily through its role in enhancing the translation of c-MYC mRNA. Given that IGF2BP2 is not an ideal target for small-molecular drugs, we performed RNA immunoprecipitation sequencing (RIP-Seq) and found circRNA-BISC as a potent IGF2BP2 repressor. BISC effectively inhibited both c-MYC translation and BETi resistance. Notably, BISC contains a “CAC-linker-XGGX” motif that specifically binds IGF2BP2 rather than to IGF2BP1 and IGF2BP3. The efficacy and selectivity of BISC in targeting IGF2BP2 prompted further exploration of BISC-based RNA therapeutics for TNBC. In vitro transcribed and circularized BISC, when combined with the BETi OTX-015, demonstrated impressive tumor regression in BETi-resistant TNBC models without detectable toxicity. These findings establish BISC as a potent IGF2BP2 repressor and highlight the feasibility of circRNA-based therapeutic strategies to overcome BETi resistance in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, State Key Laboratory of Respiratory Health and Multimorbidity, West Ch…
- Tianfu Jincheng Laboratory, Chengdu 610212, China.
ORCID-Profile: Jiawei Guo, Ke Li, Shuangyan Tan, Shuang Chen, Yingying Duan, Yong Peng
Förderung
- National Natural Science Foundation of China
- Science and Technology Foundation of Sichuan Province, China
- the Fundamental Research Funds for the Central Universities
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
Zitieren
APA
Guo, J., Li, K., Ming, Y., Pan, Y., Tan, S., Ma, H., Chen, S., Duan, Y., & Peng, Y. (2025). A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2504320122
Vancouver
Guo J, Li K, Ming Y, Pan Y, Tan S, Ma H, et al. A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2504320122
BibTeX
@article{Guo2025,
author = {Guo, Jiawei and Li, Ke and Ming, Yue and Pan, Yitong and Tan, Shuangyan and Ma, Hulin and Chen, Shuang and Duan, Yingying and Peng, Yong},
title = {A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2504320122}
}
EUVIMED